Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

737
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
737
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

3.0K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PROTAC-mediated regulation of programmed cell death: From molecular mechanisms to therapeutic breakthroughs.

Innovation (Cambridge (Mass.))·2026
Same author

Cardiotoxicity of Targeted Therapies in Hematologic Malignancies: From Molecular Mechanisms to Clinical Management.

Current treatment options in oncology·2026
Same author

WTAP-mediated m6A modification of UBE2K drives the malignant progression of gastric cancer.

Biochimica et biophysica acta. Molecular basis of disease·2026
Same author

Efficacy and safety of camrelizumab plus apatinib in advanced urachal cancer (RUN-SC-0102): a single-arm, multicentre, phase 2 trial in China.

EClinicalMedicine·2026
Same author

Antibody targeting of the TNF-TNFR2 axis to overcome tumor immune resistance.

Frontiers in immunology·2026
Same author

Repurposing the Neurokinin-1 receptor antagonist Aprepitant to eradicate relapsed/refractory acute lymphoblastic leukemia via mitochondria-driven necroptosis.

Cancer letters·2026

Related Experiment Video

Updated: Dec 25, 2025

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.6K

FBW7 in hematological tumors.

Qiaojuan Zhu1, Linjun Hu2, Yang Guo3

  • 1The Second Clinical Medical Department, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310014, P.R. China.

Oncology Letters
|March 21, 2020
PubMed
Summary
This summary is machine-generated.

F-box and WD repeat domain-containing protein 7 (FBW7) is a tumor suppressor crucial for regulating cell growth. Aberrant FBW7 expression drives hematological tumors, presenting a potential therapeutic target.

Keywords:
F-box and WD repeat domain-containing protein 7T cell acute lymphoblastic leukemiaadult T cell leukemia/lymphomachronic lymphocytic leukemiahematological tumormultiple myelomaubiquitin-proteasome system

More Related Videos

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

12.2K
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

8.2K

Related Experiment Videos

Last Updated: Dec 25, 2025

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.6K
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

12.2K
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

8.2K

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • F-box and WD repeat domain-containing protein 7 (FBW7) is an F-box protein and a key component of the Skp1-Cul1-F-box-protein E3 ubiquitin ligase complex.
  • FBW7 acts as a tumor suppressor by targeting critical proteins like cyclin E, c-Myc, and Notch for ubiquitination and degradation.
  • Mutations and deletions in the FBW7 gene are frequently observed in various human cancers, highlighting its role in tumorigenesis.

Purpose of the Study:

  • To review the latest findings on the role of FBW7 in hematological tumors.
  • To elucidate the involvement of FBW7 in the development of hematological malignancies.
  • To identify FBW7 as a potential therapeutic target for hematological cancers.

Main Methods:

  • Literature review of recent studies on FBW7 function in hematological malignancies.
  • Analysis of FBW7's role as a substrate recognition subunit in the E3 ubiquitin ligase complex.
  • Examination of FBW7's impact on the stability of key oncogenic proteins and transcription factors.

Main Results:

  • FBW7 dysregulation is implicated in the pathogenesis of hematological tumors, including T cell acute lymphoblastic leukemia, adult T cell leukemia/lymphoma, chronic lymphocytic leukemia, and multiple myeloma.
  • FBW7's tumor-suppressive function is compromised in these malignancies due to mutations or altered expression.
  • The aberrant expression of FBW7 contributes to the uncontrolled proliferation and survival of cancer cells.

Conclusions:

  • FBW7 plays a critical role in preventing the development of hematological tumors.
  • Targeting FBW7 or its regulatory pathways may offer a novel therapeutic strategy for hematological malignancies.
  • Further research into FBW7's mechanisms in hematological cancers is warranted for clinical application.